RedHill Biopharma (RDHL) Enters Research Collaboration with Stanford for YELIVA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq lags peers as Netflix, chip stocks drag; AmEx lifts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Wall St indexes split, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Jabil falls after placing CEO on paid leave amid internal investigation
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
RedHill Biopharma Announces Research Collaboration with Stanford University for YELIVA™
September 12, 2016 8:00 AM EDTTEL-AVIV, Israel, Sept. 12, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ: RDHL) (TASE: RDHL) (RedHill or the Company), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced a research collaboration with Stanford University School of Medicine (Stanford) for the evaluation of RedHills proprietary Phase II-stage drug, YELIVA (ABC294640).
The research collaboration is intended to complement RedHills planned Phase Ib clinical study to evaluate YELIVA as a radioprotectant for prevention... More
